p.124 抽出テキスト

1175. Sabater-Molina M, Saura D, Garcia-Molina Saez E, Gonzalez-Carrillo J, Polo L, Perez-Sanchez I, et al. A novel founder mutation in MYBPC3: phenotypic comparison with the most prevalent MYBPC3 mutation in Spain. Rev Esp Cardiol (Engl Ed) 2017; 70:105–114. https://doi.org/10.1016/j.recesp.2016.06.025 1176. Adalsteinsdottir B, Burke M, Maron BJ, Danielsen R, Lopez B, Diez J, et al. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart 2020;7:e001220. https://doi.org/10.1136/ openhrt-2019-001220 1177. Lakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, et al. Associations between female sex, sarcomere variants, and clinical outcomes in hypertrophic cardiomyopathy. Circ Genom Precis Med 2021;14:e003062. https://doi.org/10.1161/ CIRCGEN.120.003062 1178. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol 2020;5:73–80. https://doi.org/10.1001/ jamacardio.2019.4534 1179. Batzner A, Aicha D, Pfeiffer B, Neugebauer A, Seggewiss H. Sex-related differences in symptomatic patients with hypertrophic obstructive cardiomyopathy – time for a new definition? Int J Cardiol 2021;328:117–121. https://doi.org/10.1016/j.ijcard. 2020.12.039 1180. Sreenivasan J, Khan MS, Kaul R, Bandyopadhyay D, Hooda U, Aronow WS, et al. Sex differences in the outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv 2021;14:930–932. https://doi.org/ 10.1016/j.jcin.2020.10.002 1181. Meghji Z, Nguyen A, Fatima B, Geske JB, Nishimura RA, Ommen SR, et al. Survival differences in women and men after septal myectomy for obstructive hypertrophic cardiomyopathy. JAMA Cardiol 2019;4:237–245. https://doi.org/10.1001/jamacardio. 2019.0084 1182. Butters A, Lakdawala NK, Ingles J. Sex differences in hypertrophic cardiomyopathy: interaction with genetics and environment. Curr Heart Fail Rep 2021;18:264–273. https://doi.org/10.1007/s11897-021-00526-x 1183. Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy. J Am Heart Assoc 2019;8:e012041. https://doi.org/10.1161/JAHA.119.012041 1184. D’Amario D, Camilli M, Migliaro S, Canonico F, Galli M, Arcudi A, et al. Sex-related differences in dilated cardiomyopathy with a focus on cardiac dysfunction in oncology. Curr Cardiol Rep 2020;22:102. https://doi.org/10.1007/s11886-020-01377-z 1185. Vissing CR, Rasmussen TB, Dybro AM, Olesen MS, Pedersen LN, Jensen M, et al. Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, arrhythmias, response to treatment and sex differences. J Med Genet 2021;58:832–841. https://doi.org/10.1136/jmedgenet-2020-107178 1186. Dominguez F, Cuenca S, Bilinska Z, Toro R, Villard E, Barriales-Villa R, et al. Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. J Am Coll Cardiol 2018;72:2471–2481. https://doi.org/10.1016/j.jacc.2018.08.2181 1187. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151–2158. https://doi.org/10.1056/NEJMoa033088 1188. Halliday BP, Gulati A, Ali A, Newsome S, Lota A, Tayal U, et al. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. Eur J Heart Fail 2018;20:1392–1400. https://doi.org/10.1002/ejhf.1216 1189. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366: 619–628. https://doi.org/10.1056/NEJMoa1110186 1190. Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation 2017;136:2068–2082. https://doi.org/10.1161/ CIRCULATIONAHA.117.030792 1191. Choudhary N, Tompkins C, Polonsky B, McNitt S, Calkins H, Mark Estes NA, et al. Clinical presentation and outcomes by sex in arrhythmogenic right ventricular cardiomyopathy: findings from the North American ARVC registry. J Cardiovasc Electrophysiol 2016;27:555–562. https://doi.org/10.1111/jce.12947 1192. Akdis D, Saguner AM, Shah K, Wei C, Medeiros-Domingo A, von Eckardstein A, et al. Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/ dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome. Eur Heart J 2017;38:1498–1508. https://doi.org/10.1093/ eurheartj/ehx011 1193. Kimura Y, Noda T, Otsuka Y, Wada M, Nakajima I, Ishibashi K, et al. Potentially lethal ventricular arrhythmias and heart failure in arrhythmogenic right ventricular cardiomyopathy: what are the differences between men and women? JACC Clin Electrophysiol 2016;2:546–555. https://doi.org/10.1016/j.jacep.2016.02.019 1194. Hoorntje ET, Te Rijdt WP, James CA, Pilichou K, Basso C, Judge DP, et al. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovasc Res 2017;113:1521–1531. https://doi.org/10.1093/cvr/cvx150 1195. Rootwelt-Norberg C, Lie OH, Chivulescu M, Castrini AI, Sarvari SI, Lyseggen E, et al. Sex differences in disease progression and arrhythmic risk in patients with arrhythmogenic cardiomyopathy. Europace 2021;23:1084–1091. https://doi.org/10.1093/ europace/euab077 1196. Lopes LR, Losi MA, Sheikh N, Laroche C, Charron P, Gimeno J, et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. Eur Heart J Qual Care Clin Outcomes 2022;9:42–53. https://doi.org/10.1093/ ehjqcco/qcac006 1197. Wasserstrum Y, Barriales-Villa R, Fernandez-Fernandez X, Adler Y, Lotan D, Peled Y, et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J 2019;40:1671–1677. https://doi.org/10.1093/eurheartj/ ehy625 1198. Limongelli G, Monda E, D’Aponte A, Caiazza M, Rubino M, Esposito A, et al. Combined effect of Mediterranean diet and aerobic exercise on weight loss and clinical status in obese symptomatic patients with hypertrophic cardiomyopathy. Heart Fail Clin 2021;17:303–313. https://doi.org/10.1016/j.hfc.2021.01.003 1199. Asatryan B, Asimaki A, Landstrom AP, Khanji MY, Odening KE, Cooper LT, et al. Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review. Circulation 2021;144:1646–1655. https://doi.org/10.1161/ CIRCULATIONAHA.121.055890 1200. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. https://doi.org/10.1183/13993003.00547-2020 1201. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720. https://doi. org/10.1056/NEJMoa2002032 1202. Capacity-Covid Collaborative Consortium, Leoss Study Group. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J 2022;43: 1104–1120. https://doi.org/10.1093/eurheartj/ehab656 1203. Omidi F, Hajikhani B, Kazemi SN, Tajbakhsh A, Riazi S, Mirsaeidi M, et al. COVID-19 and cardiomyopathy: a systematic review. Front Cardiovasc Med 2021;8:695206. https://doi.org/10.3389/fcvm.2021.695206 1204. Gimeno JR, Olivotto I, Rodriguez AI, Ho CY, Fernandez A, Quiroga A, et al. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Fail 2022;9:2189–2198. https://doi.org/ 10.1002/ehf2.13964 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026